These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29574039)

  • 1. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
    Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
    Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
    Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
    Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
    Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
    Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.
    Berry JS; Vreeland TJ; Hale DF; Jackson DO; Trappey AF; Greene JM; Hardin MO; Herbert GS; Clifton GT; Peoples GE
    J Cancer; 2017; 8(7):1255-1262. PubMed ID: 28607601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
    Jackson DO; Byrd K; Vreeland TJ; Hale DF; Herbert GS; Greene JM; Schneble EJ; Berry JS; Trappey AF; Clifton GT; Hardin MO; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwell GL; Peoples GE
    Oncotarget; 2017 Feb; 8(9):15912-15923. PubMed ID: 27852036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
    Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
    Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
    Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
    Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.
    Kalli KR; Block MS; Kasi PM; Erskine CL; Hobday TJ; Dietz A; Padley D; Gustafson MP; Shreeder B; Puglisi-Knutson D; Visscher DW; Mangskau TK; Wilson G; Knutson KL
    Clin Cancer Res; 2018 Jul; 24(13):3014-3025. PubMed ID: 29545464
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gupta A; O'Cearbhaill RE; Block MS; Hamilton E; Konner JA; Knutson KL; Potts J; Garrett G; Kenney RT; Wenham RM;
    Gynecol Oncol; 2024 Oct; 189():90-97. PubMed ID: 39068739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
    Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
    J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
    Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
    Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.
    Murahashi M; Tsuruta T; Yamada K; Hijikata Y; Ogata H; Kishimoto J; Yoshimura S; Hikichi T; Nakanishi Y; Tani K
    Anticancer Res; 2021 Mar; 41(3):1485-1496. PubMed ID: 33788741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    J Transl Med; 2014 Mar; 12():61. PubMed ID: 24606884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.